Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Kronos Bio, Inc. KRON NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
64/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$1.63
+85.2%

Kronos Bio, Inc. (KRON) is a Biotechnology company in the Healthcare sector, currently trading at $0.88. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is KRON = $2 (+85.2% upside).

Financials: revenue is $10M, +56.6%/yr average growth. Net income is $86M (loss), growing at +16.6%/yr. Net profit margin is -874.1% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $25M against $88M equity (Debt-to-Equity (D/E) ratio 0.28, conservative). Current ratio is 7.54 (strong liquidity). Debt-to-assets is 20%. Total assets: $124M.

Analyst outlook: 5 / 5 analysts rate KRON as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

$1.63
▲ 85.23% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Kronos Bio, Inc., the average price target is $1.63, with a high forecast of $2.25, and a low forecast of $1.00.
Highest Price Target
$2.25
Average Price Target
$1.63
Lowest Price Target
$1.00

KRON SharesGrow Score Overview

74/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 90/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — KRON

✓
VALUE Pass
100/100
KRON trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $2, implying +127.3% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
90/100
KRON: +56.6%/yr revenue is, +16.6%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet KRON: Debt-to-Equity (D/E) ratio 0.28 (conservative), Current ratio is 7.54 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
KRON: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 5 / 5 analysts rate KRON as buy (100%). Analyst consensus target is $2 (+127.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
KRON: Net profit margin is -874.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.65-1.46
Volume53.69K
Avg Volume (30D)855.96K
Market Cap$53.65M
Beta (1Y)1.64
Share Statistics
EPS (TTM)-1.43
Shares Outstanding$60.07M
IPO Date2020-10-09
Employees8
CEODeborah A. Knobelman
Financial Highlights & Ratios
Revenue (TTM)$9.85M
Gross Profit$9.85M
EBITDA$-61.72M
Net Income$-86.08M
Operating Income$-92.89M
Total Cash$112.42M
Total Debt$24.9M
Net Debt$-59.67M
Total Assets$124.36M
Price / Earnings (P/E)-0.6
Price / Sales (P/S)5.45
Analyst Forecast
1Y Price Target$1.63
Target High$2.25
Target Low$1.00
Upside+84.7%
Rating ConsensusBuy
Analysts Covering5
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS50107A1043

Price Chart

Track all markets on TradingView
KRON
Kronos Bio, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.65 52WK RANGE 1.46

People Also View

MRUS
MRUS
Merus N.V.
$90.00
+0.00%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.19
+7.40%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 LYEL
LYEL
Lyell Immunopharma, Inc.
$23.37
-5.77%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message